Chennai, NFAPost: Abbott and leading online pharmacy and healthcare platform, 1mg, have announced their collaboration to make Abbott’s continuous glucose monitoring products available online, including its professional flash glucose monitoring system, FreeStyle Libre Pro.
Patients in India can upload a healthcare practitioner’s prescription and purchase the product online on 1mg. An on-site phlebotomy service will be provided at the patient’s home with a phlebotomist helping the patient administer the sensor and take readings of the data after 14 days, enabling them to start using the device, Abbott said.
Abbott′s FreeStyle Libre Pro consists of a small, round sensor — slightly larger than a 10-rupee coin. A phlebotomist applies the discreet, water-resistant and disposable sensor on the back of the upper arm of a patient. The sensor is held in place with a self-adhesive pad and remains on the back of the upper arm for up to 14 days, requiring no patient interaction with the sensor.
“Innovations like the FreeStyle Libre Pro system have transformed the way people manage their glucose levels,” said Abbott’s diabetes care business in India general manager Kalyan Sattaru.
“Making this life-changing technology available online enables more patients to remotely access the care they need, which is especially critical and timely given the current pandemic environment. Our world-leading continuous glucose monitoring will help many more people in India take charge of their condition, and ultimately improve their health,” he added.
Commenting on the partnership, 1mg Co-Founder and CEO Prashant Tandon said, “1mg provides a comprehensive suite of high-quality services for diabetes care, ranging from medicines to doctor consultations, delivered to patients in the comfort and safety of their homes. We are pleased to bring Abbott’s continuous glucose monitoring solutions closer to Indian homes by ensuring easy online access and expert phlebotomy services for FreeStyle Libre Pro application.”
India’s population living with diabetes today is 77 million, and that number is expected to cross 100 million by 2030. Poor diabetes control, a factor that has been observed in the Indian population with diabetes, puts them at increased risk of health complications including nerve problems, heart diseases, retinopathy and foot ulcers.
Continuous glucose monitoring devices provides a visual display of a patient’s glucose levels over time and how they vary. With this information, patients and their doctors can personalise a treatment plan to help improve patient glucose levels have a greater time in range, i.e., they remain within the recommended limits for longer durations. Abbott’s FreeStyle Libre Pro was launched in India in 2015. Abbott’s glucose monitoring portfolio has benefitted more than 2 million people living with diabetes worldwide.
In India, Abbott was established in 1910, and is one of the country’s oldest and most admired healthcare companies. With over 12,000 employees in the country, Abbott in India is helping to meet the healthcare needs of consumers, patients and doctors throughout urban and rural India.
